XM does not provide services to residents of the United States of America.
P
P

Pfizer

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Collaboration software maker Smartsheet fields buyout interest, sources say

EXCLUSIVE-Collaboration software maker Smartsheet fields buyout interest, sources say Adds share reaction in paragraph 4 By Milana Vinn and Anirban Sen July 18 (Reuters) - Smartsheet SMAR.N , a U.S. maker of workplace collaboration software with a market value of $6.6 billion, has tapped investment bankers after attracting acquisition interest from buyout firms, according to people familiar with the matter.
C
P

Collaboration software maker Smartsheet fields buyout interest, sources say

EXCLUSIVE-Collaboration software maker Smartsheet fields buyout interest, sources say By Milana Vinn and Anirban Sen July 18 (Reuters) - Smartsheet SMAR.N , a U.S. maker of workplace collaboration software with a market value of $6.3 billion, has tapped investment bankers after attracting acquisition interest from buyout firms, according to people familiar with the matter.
C
P

Novo Nordisk obesity feast no longer a free lunch

BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, July 18 (Reuters Breakingviews) - Novo Nordisk NOVOb.CO is going to have to work hard to justify its bulging valuation. The $603 billion obesity drug maker’s shares have more than trebled since 2021 thanks to insatiable appetite for its weight-loss drug.
A
P
R
I

Valneva Says Co And Pfizer Announce Primary Vaccination Series Completion

BRIEF-Valneva Says Co And Pfizer Announce Primary Vaccination Series Completion July 17 (Reuters) - Valneva SE VLS.PA : PHASE 3 VALOR LYME DISEASE TRIAL: VALNEVA AND PFIZER ANNOUNCE PRIMARY VACCINATION SERIES COMPLETION VALNEVA - PRIMARY VACCINATION SERIES TO BE FOLLOWED BY A BOOSTER APPROXIMATELY ONE YEAR AFTER COMPLETION VALNEVA SE: PFIZER PLANS TO SUBMIT A BIOLOGICS LICENSE APPLICATION (BLA) TO U.S.
P

Mark Cuban's Cost Plus to import penicillin to address US shortage (July 17)

CORRECTED-Mark Cuban's Cost Plus to import penicillin to address US shortage (July 17) Removes reference in July 17 story to Pfizer's pediatric version of Bicillin-L-A in paragraph 3 July 17 (Reuters) - Mark Cuban's Cost Plus Drug Company said on Wednesday that it is working with the U.S. Food and Drug Administration to import and distribute penicillin in the country temporarily.
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.